Ron Bentsur
Chairman & CEO, Director, 10% Owner · Nuvectis Pharma, Inc.
- 2024
- Jul 1, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Ron Bentsur files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Marlio Charles Mosseri - $916K in NVCT purchases and sales in the last 12 months
- Robert Scott Goodman - $200K in XAIR purchases and sales in the last 12 months
- Juan Sanchez - $75K in NVCT purchases and sales in the last 12 months
- Matthew L. Kaplan - $64K in NVCT purchases and sales in the last 12 months
- Yi-Chien Lin - $62K in XAIR purchases and sales in the last 12 months
- Daniel J. Moorhead - $25K in XAIR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Ron Bentsur?
Ron Bentsur is a corporate insider, tracked as Chairman & CEO, Director, 10% Owner of Nuvectis Pharma, Inc. (NVCT). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Ron Bentsur last file a Form 4?
The most recent primary Form 4 on record is dated 1 July 2026, one of 5 filings going back to 2024.
Has Ron Bentsur been buying or selling stock?
Recorded transactions: 4 open-market purchases ($398K) and 0 open-market sales across all tracked filings.
